At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.

Derived from Strategic Transactions, EBI’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals– and then categorized by type –Acquisition, Alliance, or Financing.

Bayer Chairman Marijn Dekkers says Schiff’s products will complement its existing nutritionals business and provide marketing synergies with some OTCs. Schiff’s Move Free for joint health, MegaRed for heart health, Airborne for immunity and Digestive Advantage probiotics accounted for 70% of its fiscal 2012 sales.

Bayer Chairman Marijn Dekkers says Schiff’s products will complement its existing nutritionals business and provide marketing synergies with some OTCs. Schiff’s Move Free for joint health, MegaRed for heart health, Airborne for immunity and Digestive Advantage probiotics accounted for 70% of its fiscal 2012 sales.